8-Chloro-6,11-dihydro-6-methyl-5H-pyrido[3,2-c][1]benzazepine-11-one | 205984-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 8-Chloro-6,11-dihydro-6-methyl-5H-pyrido[3,2-c][1]benzazepine-11-one
• 英文别名: 8-chloro-6-methyl-5H-pyrido[3,2-c][1]benzazepin-11-one
• CAS: 205984-70-9
• 化学式: C₁₄H₁₁ClN₂O
• 分子量: 258.707
• InChiKey: PPVKJJLBKMLTBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-Chloro-6,11-dihydro-6-methyl-5H-pyrido[3,2-c][1]benzazepine-11-one 在 sodium tetrahydroborate 作用下， 以 甲醇 、 正己烷 、 二氯甲烷 为溶剂， 生成 8-Chloro-6,11-dihydro-6-methyl-5H-pyrido[3,2-c][1]benzazepin-11-ol
  参考文献：
  名称：

  TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS

  摘要：

  公开号：

  EP1021448B1

文献信息

• Tricyclic compounds having activity as RAS-FPT inhibitors
  申请人：Schering Corporation

  公开号：US06130229A1

  公开（公告）日：2000-10-10

  Compounds of Formula I: ##STR1## wherein: X.sup.1 is hydrogen, halogen, CF.sub.3, nitro, NH.sub.2 or lower alkyl; each X.sup.2 is independently selected from the group consisting of hydrogen, halogen, lower alkoxy and lower alkyl; n is 1 or 2; Y is selected from the group consisting of S(O).sub.p, O, and NR.sup.5, wherein p is 0, 1 or 2, and R.sup.5 is hydrogen, alkyl, aryl, cycloalkyl, loweralkoxycarbonyl, aminocarbonyl or acyl; R.sup.1 and R.sup.2, which may be the same or different, are selected from the group consisting of hydrogen and lower alkyl groups, or taken together can form an oxygen atom when Y is NR.sup.5 ; A . . . is C=, CH-- or N--; R is --CZ--Y.sup.1 --Y.sup.2 --R.sup.3, wherein: Z is O, =CH--CN, or =N--CN; one of Y.sup.1 and Y.sup.2 is a bond, --CO--, O, S, or --NR.sup.4 --, and the other is (CH.sub.2).sub.m, where m is 0 or an integer of 1 to 4, and R.sup.4 is H or alkyl, with the proviso that when Z is O and m is 0 then Y.sup.1 or Y.sup.2 is selected from --CO--, O, S, or --NR.sup.4 ; R.sup.3 is aryl, heteroaryl or heterocycloalkyl, with the proviso that R.sup.3 can also be lower alkyl when Z is =N--CN; and their pharmaceutically acceptable acid addition salts; have activity as Ras-FPT inhibitors. They can be used, e.g., in pharmaceutical compositions, for inhibiting the abnormal growth of cells and for inhibiting proliferative diseases. Processes for their preparation, and useful intermediates, are also disclosed.

  化合物的公式I：##STR1## 其中：X.sup.1为氢、卤素、CF.sub.3、硝基、NH.sub.2或低级烷基；每个X.sup.2独立地选自氢、卤素、低级烷氧基和低级烷基的群；n为1或2；Y选自S（O）.sub.p、O和NR.sup.5的群，其中p为0、1或2，R.sup.5为氢、烷基、芳基、环烷基、低级烷氧羰基、氨基羰基或酰基；R.sup.1和R.sup.2，可以相同也可以不同，选自氢和低级烷基，或者当Y为NR.sup.5时，它们可以连在一起形成一个氧原子；A . . . 为C=、CH-或N-；R为--CZ--Y.sup.1--Y.sup.2--R.sup.3，其中：Z为O、=CH-CN或=N-CN；Y.sup.1和Y.sup.2中的一个为键、--CO--、O、S或--NR.sup.4--，另一个为（CH.sub.2）.sub.m，其中m为0或1到4的整数，R.sup.4为H或烷基，但当Z为O且m为0时，Y.sup.1或Y.sup.2选自--CO--、O、S或--NR.sup.4；R.sup.3为芳基、杂芳基或杂环烷基，但当Z为=N-CN时，R.sup.3也可以是低级烷基；它们的药学上可接受的酸盐具有Ras-FPT抑制剂的活性。它们可以用于制备制药组合物，用于抑制细胞的异常生长和抑制增殖性疾病。本文还公开了它们的制备方法和有用的中间体。
• US6130229A
  申请人：——

  公开号：US6130229A

  公开（公告）日：2000-10-10
• [EN] TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS<br/>[FR] COMPOSES TRICYCLIQUES PRESENTANT UNE ACTIVITE D'INHIBITEURS DE LA Ras-FPT
  申请人：SCHERING CORPORATION

  公开号：WO1998015556A1

  公开（公告）日：1998-04-16

  (EN) Compounds of formula (I), wherein: X1 is hydrogen, halogen, CF3, nitro, NH2 or lower alkyl; each X2 is independently selected from the group consisting of hydrogen, halogen, lower alkoxy and lower alkyl; n is 1 or 2; Y is selected from the group consisting of S(O)p, O, and NR5, wherein p is 0, 1 or 2, and R5 is hydrogen, alkyl, aryl, cycloalkyl, loweralkoxycarbonyl, aminocarbonyl or acyl; R1 and R2, which may be the same or different, are selected from the group consisting of hydrogen and lower alkyl groups, or taken together can form an oxygen atom when Y is NR5; A..... is C=, CH- or N-; R is -CZ-Y1-Y2-R3, wherein: Z is O, =CH-CN, or =N-CN; one of Y1 and Y2 is a bond, -CO-, O, S, or -NR4-, and the other is (CH2)m, where m is 0 or an integer of 1 to 4, and R4 is H or alkyl, with the previso that when Z is O and m is 0 then Y1 or Y2 is selected form -CO-, O, S, or -NR4; R3 is aryl, heteroaryl or heterocycloalkyl, with proviso that R3 can also be lower alkyl when Z is =N-CN; and their pharmaceutically acceptable acid additions salts; have activity as Ras-FPT inhibitors. They can be used, e.g., in pharmaceutical compositions, for inhibiting the abnormal growth of cells and for inhibiting proliferative diseases. Processes for their preparation, and useful intermediates, are also disclosed.(FR) L'invention porte sur des composés de formule (I) dans laquelle: X1 est H, halogène, CF3, nitro, NH2, ou alkyle inférieur; chacun des X2 est choisi indépendamment parmi H, alkoxy inférieur, ou alkyle inférieur; n est 1 ou 2; Y est choisi parmi S(O)p, O et NR5, p étant 0, 1 ou 2, et R5 étant H, alkyle, aryle, cycloalkyle, alkoxy inférieur carbonyle, aminocarbonyle ou acyle; R1 et R2 qui peuvent être identiques ou différents sont choisis parmi des groupes H ou alkyle inférieur, ou peuvent former ensemble un atome d'oxygène lorsque Y est NR5; A..... est C=, CH- ou N-; R est -CZ-Y1-Y2-R3, où Z est O, =CH-CN, ou =N-CN; l'un des Y1 et Y2 est une liaison, -CO-, O, S, ou -NR4-, et l'autre est (CH2)m, m étant = ou un entier de 1 à 4, et R4 étant H ou alkyle sous réserve que si Z est O, et m est 0, Y1 et Y2 soient choisis parmi -CO-, O, S, ou -NR4; R3 est aryle, hétéroaryle ou hétérocycloalkyle, sous réserve que R3 puisse également être alkyle inférieur lorsque Z est =N-CN. L'invention porte également sur leurs sels acidifiants pharmacocompatibles qui peuvent être utilisés par exemple dans des préparations pharmaceutiques pour inhiber la croissance cellulaire anormale et les maladies proliférantes; elle porte en outre sur leur préparation et sur des intermédiaires utiles.
• TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS
  申请人：SCHERING CORPORATION

  公开号：EP1021448B1

  公开（公告）日：2003-05-02